Boston Scientific (BSX)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$44.80-1.09%
Close 2026-07-08 · 1-day change
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→QuarterlyIQ Insights · BSX
How bumpy this stock is to hold — the size of a typical vs. bad-day move, what macro factors push and pull it, and how its valuation compares to peers and its own history.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$127.
How much price usually moves either way.
On a bad day, this stock has moved -$277.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,053.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
How today's macro reading is pushing this stock. Green helps, red hurts; bar length shows the relative size of the push.
Top drivers today: Rates, Growth, Labor, Inflation
Realized vol (252d): 36.7% · Beta (1y, vs XLV): 0.52
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.84 → $0.84 (-0.3% / 30d). 0 raised, 14 cut, 22 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 87% of analysts rate Buy.
3 PT revisions / 30d. Avg target 43.3% above current price.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-07-08.
A rolling correlation matrix vs. the S&P 500, the sector ETF, and the full peer set is on the way, alongside backtest cohort evidence (historical returns for stocks that previously shared this signal profile).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.